Expert Discusses Add-On Study Design for Ibrutinib as Treatment for Chronic Lymphocytic Leukemia

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She discussed the study design and what the sample demographics were.

Related Content:

ConferenceInterviewsHospitalSpecialty Pharmacy
Targeting G Protein–Coupled Receptors With CAR T-Cell Therapy Shows Promise Treating Multiple Myeloma
Dostarlimab Plus Chemotherapy Shows Promise in Non-Small Cell Lung Cancer
Whole Grain Consumption Associated With Reduced Risk of Premature Coronary Artery Disease